MicroRNAs在肺癌发病和诊疗中作用的研究进展

Research progress of Micro RNAs in pathogenesis and treatment of lung cancer

肺癌是目前死亡率最高的的恶性肿瘤,且整体5年生存率偏低。尽管近年来放化疗技术和手术水平有了很大程度的提高,但肺癌的病死率基本保持不变,因此对肺癌的早期诊断和预防一直是近些年恶性肿瘤研究的热点。Micro RNA是一种非编码小分子RNA,可以调控50%以上的蛋白编码基因,且Micro RNA在血液和组织中都很稳定,因此它可以作为肺癌的标志物运用于肺癌的早期诊断。随着Micro RNA理论的研究进一步深入,将为肺癌的早期诊断和治疗带来了新的思路。

Lung cancer have the highest mortality rate in all malignant tumors currently. Also, its five-year survival rate is very low. Although the chemotherapy and operation level has been greatly improved, the mortality of lung cancer remains unchanged. It is very important that prevent, anticipate, and diagnose the cancer as soon as possible. Micro RNAs(mi RNAs)are small non- coding RNA molecules capable of regulating expression of over 50% of protein- coding genes. The RNA molecules are stable in tissues and blood, so it can tend to be a biomarker in early diagnosis of lung cancer. Here, this is a review on the roles of mi RNAs for possible ways to prevent lung cancer in clinical trials. With the improving understanding of the pathogenesis in lung cancer at the molecular, especially the study on Micro RNA theory, brings new hope for the early diagnosis and treatment of lung cancer.